On March 10, 2022 Manhattan BioSolutions, an emerging biotechnology company focused on the development of innovative biologic therapies for the treatment of advanced and metastatic cancers, reported that it has been awarded grant funding as part of Round 3 of the New Jersey Commission on Science, Innovation, and Technology Direct Financial Assistance component (Phase I&II) of the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Program (STTR) (Press release, Manhattan BioSolutions, MAR 10, 2022, View Source [SID1234609874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This award will enable early-stage preclinical validation of therapeutic leads previously supported by the SBIR and STTR Phase I grants. Novel therapeutic platforms developed by Manhattan BioSolutions leverage pathogen-specific immune responses to fight disease, particularly cancers. Dr. Borys Shor, CEO of Manhattan BioSolutions, commented: "This award expands our capacity to discover novel therapies at the intersection of innate immunity, age-related diseases, and cancer. We expect to have a deep pipeline of discovery stage products by year-end and bring those into human trials in 2023."